In focus · trending topic

strongbridge

2 stories · following the connections

Strongbridge Biopharma plc Provides Updates on KEVEYIS® Launch and Recent Business Highlights, and Reports Second Quarter 2017 Financial Results

By Nasdaq OMXAug 7, 2017, 11:00 AM UTC

Strongbridge Biopharma plc Completes Target Enrollment of 90 Patients in the Phase 3 SONICS Study Evaluating RECORLEV™ (levoketoconazole) in Endogenous Cushing’s Syndrome

By Nasdaq OMXJun 27, 2017, 11:30 AM UTC